Congresswoman Donna Shalala to join leading scientists, developers, regulators, and policy/business decision-makers who are seeking to accelerate translation of major scientific discoveries into products that slow the aging process and onset of major chronic diseases.
Read Press Release(i) Study shows Philogen's proprietary immunocytokines are effective treatment for brain tumors.
(ii) Early promising findings from Philogen's Phase I/II study investigating the safety and efficacy of L19TNF monotherapy in patients with glioblastoma.
(iii) Philogen's proprietary cancer treatment found to be safe and well-tolerated.
This marks the 11th U.S. provisional patent application filed by GBS covering the use of CCCM™ for unique medical disorders, creating an IP portfolio that contains formulas for up to 50 potential therapeutic indications.
Read Press ReleaseWith the AWS Partner Network designations of Advanced Consulting and the Life Sciences Competency, PTP continues to develop its cloud migration, management, optimization and security services to help its customers reach their business goals.
Read Press ReleaseMr. Riley to Lead Corporate Development Efforts as Company Targets New Clinical Applications for its Proprietary, FDA-Cleared Blink Reflex Technology
Read Press ReleaseBased on data from a two-year study, GBS's CCCM were designed for the treatment of Cytokine Storm Syndromes, while preserving anti-viral immune reactions
Read Press ReleaseNew digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in pre-clinical tissues and adult NASH biopsies at the Digital International Liver CongressTM 2020
Read Press ReleaseTechnology, expertise from UK's Mucokinetica to accelerate repurposing of generic remedy nafamostat for COVID-19 oral, inhalation therapy
Read Press Release